Chronic Disease Management- Diabetes. 43 year old male presents with one month history of feeling very thirsty and hungry. Urinating 5 times every night.

Slides:



Advertisements
Similar presentations
Oral Hypoglycemic Drugs And Classifications
Advertisements

In-Patient Management of Hyperglycemia Rey Vivo, MD Assistant Professor of Medicine Texas Tech University Health Sciences Center.
The New HbA1c HbA1c – DCCT (%) HbA1c – IFFC (mmol/mol)
Diabetes (abridged!). Who needs screening for DM? Age >45 Obese – BMI >25 1 st degree relative with DM Racial groups: –African American –Hispanic American.
Krisa Christian MD. Diabetes 1 in every 14 Americans has diabetes The disease accounts for 200,000 deaths, 82,000 amputations, 44,400 cases of ESRD, and.
DIABETES MEDICATION UPDATE A. Sami Wood, MS, RD/LD,CDE Center For Diabetes Education OSUMC.
Diabesity Management Colette Walter, NP. Objectives 1. Pharmacologic management and understanding of treatment related to the overweight diabetic patient.
Updates in Diabetes Management Kim Tartaglia, MD August 22, 2007.
Glycemic Control Medications. Sulfonylureas (2 nd generation) Dose Size Dose/day (mg) Peak (hrs) Dose Interval Common side effects Glyburide (Micronase®,
Oral Medications to Treat Type 2 Diabetes
Combination Therapy in Type 2 Diabetes
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Barriers to Diabetes Control Mark E. Molitch, MD.
Chapter 36 Agents Used to Treat Hyperglycemia and Hypoglycemia.
Insulin therapy.
LONG TERM BENEFITS OF ORAL AGENTS
DIABETES MELLITUS DR. J. PRATHEEBA DEVI. Definition Definition Diabetes is a metabolic disorder characterized by raised levels of glucose in the blood.
PRACTICAL INSULIN USE PRACTICAL INSULIN USE or, how to think like a pancreas Oliver Z. Graham, MD Department of Internal Medicine Virtual Endocrinologist.
DIABETES MELLLITUS Strategies for Achieving Control in an Office Setting.
Drugs used in Diabetes Dr Sally Hudson. BIGUANIDES reduce output of glucose from the liver and enhances uptake and use of glucose by muscle cells ExampleADVANTAGESDISADVANTAGESCOSTCaution.
DIABETES MELLITUS THERAPY. Nutrition Therapy  Weight loss frequently is a primary goal of nutrition therapy because 80% to 90% of people with type II.
Criteria for Diagnosis of DM * Testing must be repeated on separate day. FPG is the preferred test ** Symptoms of DM IFG = Impaired fasting glucose IGT.
Diabetes in the 21 st Century 2010 Update. American Diabetes Association 2010 Guidelines – Diagnostic Criteria A1C > or = 6.5% is included as diagnostic.
Kathryn A. Hanavan ANP-BC; BC-ADM Harold Schnitzer Diabetes Health Center September 12,
Diabetes Mellitus Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
oral hypoglycemic agents
Oral Hypoglycemic Drugs
Clinical Update in Type 2 Diabetes A Case Discussion Dr. Yancey R. Holmes, MD, FACE Ohio Valley Endocrinology.
1. Question 1  What is our Global Ranking for DM ?  What is our current estimated burden?  Why is T2DM so important ?
Diabetes and You Vidya Sundaram, MD. Diabetes in Asian Indians The prevalence of diabetes in rural India is 2 percent The prevalence of diabetes in rural.
Titrating Insulin to Glycemic Target Judy Bowen, MD CIM Rotation September, 2006.
OnsetPeakDuration Rapid Acting Lispro (Humalog) min3-5 hours Aspart (Novolog)15-30 min1-3 hours3-5 hours Intermediate Acting NPH1-4 hours5-10.
Inpatient Glycemic Management
Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 3 of 3.
Journal Club 2009 年 1 月 29 日(木) 8 : 20 ~ 8 : 50 B 棟 8 階カンファレンスルーム 薬剤部 TTSP 石井 英俊.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
CLINICAL UPDATES: MANAGEMENT OF DIABETES MELLITUS.
Managing Type 2 Diabetes: Review of Recent Guidelines Gina Ryan, Pharm.D., BCPS, CDE Clinical Associate Professor Mercer University College of Pharmacy.
Oral hypoglycemic drugs
Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes
TYPE 2 DIABETES MELLITUS Cynthia Brown, MN, ANP, CDE.
October 16, 2015 Mary-Anne Doyle, MD Endocrinology and Metabolism
January 2013 Webinar: “Practical Ways to Help Get Our Diabetes Patients to Goal” Controlling the ABC’s Cases.
Type 2 diabetes treatment: Old and New Emily Szmuilowicz, MD, MS Assistant Professor of Medicine Division of Endocrinology Northwestern University.
Diabetes Crash Course: The Outpatient Setting Dr. Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University October 7, 2008
Tresiba- insulin degludec
Oral hypoglycemic drugs
Diabetes Update: Michael Gottschalk, M.D, Ph.D.
Diabetes Mellitus: Prevention & Treatment Medical surgical in nursing /02/01.
#4 Management of Diabetes Mellitus. 5 Components of Diabetes Management 5 Components of Diabetes Management Farrell, M. (2005). Textbook of Medical-Surgical.
Oral Diabetes Medications Carol Cordy, MD. Goals Understand how type 2 diabetes affects many organs and how this changes over the course of the illness.
ADDITIONAL SLIDES FOR ASSIST WITH COMPREHENSION OF LAB CONTENT-MODULE FIVE-DM DENISE TURNER, MS-N.ED, RN, CCRN.
Journal Club 9/15/11 Sanaz Sakiani, MD 1 st Year Endocrine Fellow Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics.
Dr. Mansour Alzahrani. متى اكتشف داء السكري؟ داء السكري في الحضارة الهندية والصينية القديمة اسهامات علماء المسلمين في داء السكري.
Chronic Disease Management- Diabetes Amy Shaheen, MD.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS.
This lecture was conducted during the Nephrology Unit Grand Ground by a Sub-intern under Nephrology Division, Department of Medicine in King Saud University.
Medications Used in the Treatment of Diabetes Mellitus
Insulin Initiation and Titration
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS
Diabetes Medications in the Top 200
T1DM: Insulin Initiation
oral hypoglycemic agents
Diabetes.
Insulin Delivery Systems Atlanta Diabetes Associates
Inpatient Insulin Management on the Wards
Oral hypoglycemics Jennifer R Marks, MD.
Insulin in Type 2 Diabetes
Presentation transcript:

Chronic Disease Management- Diabetes

43 year old male presents with one month history of feeling very thirsty and hungry. Urinating 5 times every night. Feels tired and worn out. PMHx: HTN Meds: HCTZ 25 mg daily PE: AF P98 BP 128/88 BMI 36 Appears well. HEENT: dry mm CV tachy. RR.

What to do now? Diagnostic criteria for Diabetes: 1) Classic symptoms + casual blood glucose >= 200 2) Fasting glucose >= 126 3) 2h Plasma glucose>=200 after OGTT (75G ) 4) Hemoglobin A1c >6.5% (NEW ADA 2010)

His casual blood sugar is 203. His casual blood sugar is 203. Does he fulfill diagnostic criteria for diabetes? Does he fulfill diagnostic criteria for diabetes? YES. Symptoms and blood sugar>200 YES. Symptoms and blood sugar>200 What treatment do you advise at this time? What treatment do you advise at this time?

Biguanides (metformin) Decreases hepatic glucose production Decreases hepatic glucose production Decrease A1c 1-2% Decrease A1c 1-2% Advantages: weight loss, no hypoglycemia, improves microvascular and macrovascular risks, decreased lipids Advantages: weight loss, no hypoglycemia, improves microvascular and macrovascular risks, decreased lipids Disadvantages: GI upset, contraindications (hepatic disease, renal disease (cr >1.5 men/> 1.4 women), CHF, rare lactic acidosis Disadvantages: GI upset, contraindications (hepatic disease, renal disease (cr >1.5 men/> 1.4 women), CHF, rare lactic acidosis Optimal dose 2000mg/d Optimal dose 2000mg/d

Sulfonylureas (glipizide, glimepiride) Increased pancreatic insulin secretion Increased pancreatic insulin secretion Reduce A1c 1-2% Reduce A1c 1-2% Advantages: decrease microvascular risk, daily dose, glucose lowering effects plateau at ½ maximal daily dose Advantages: decrease microvascular risk, daily dose, glucose lowering effects plateau at ½ maximal daily dose Disadvantages: Weight gain (2-5kg), hypoglycemia, caution with renal or hepatic impairment Disadvantages: Weight gain (2-5kg), hypoglycemia, caution with renal or hepatic impairment

Alpha-glucosidase inhibitors(acarbose) Breaks down dissacharides and more complex carbs Breaks down dissacharides and more complex carbs Delays intestinal carbohydrate absorption and reduces postprandial glucose elevation Delays intestinal carbohydrate absorption and reduces postprandial glucose elevation Reduces a1c 0.5-1% Reduces a1c 0.5-1% Neg effects: flatulence, abd discomfort Neg effects: flatulence, abd discomfort

TZD (thiazolinediones)- rosiglitazone(avandia), pioglitazone(actos) PPAR gamma ligands, increase peripheral glucose disposal PPAR gamma ligands, increase peripheral glucose disposal Reduce a1c 1-2% Reduce a1c 1-2% Neg effects- weight gain, peripheral edema, anemia, chf, increased cv events (rosiglitazone) Neg effects- weight gain, peripheral edema, anemia, chf, increased cv events (rosiglitazone)

Non-sulfonylurea secretagogues Repaglinide(prandin), nateglinide(starlix) Repaglinide(prandin), nateglinide(starlix) Increased pancreatic insulin secretion Increased pancreatic insulin secretion Targets postprandial Targets postprandial Reduce a1c 1-2% Reduce a1c 1-2% Less weight gain Less weight gain Hard to dose (3 times a day), hypoglycemia, Hard to dose (3 times a day), hypoglycemia,

Exanetide (byetta) GLP-1 (glucagon like peptide) analog GLP-1 (glucagon like peptide) analog Augments insulin secretion Augments insulin secretion slows gastric emptying, slows gastric emptying, supresses inappropriately high glucagon levels supresses inappropriately high glucagon levels leads to weight loss leads to weight loss Reduces A1c by about 1% Reduces A1c by about 1% Neg: Nausea-dose dependent and gets better; injected Neg: Nausea-dose dependent and gets better; injected

Sitagliptin (Januvia) DPP-IV inhibitors; deactivates other peptides including GLP-1 DPP-IV inhibitors; deactivates other peptides including GLP-1 Oral Oral Reduce a1c 0.5% Reduce a1c 0.5% Reduce dose for renal insufficiency Reduce dose for renal insufficiency

Insulin Weight gain Weight gain Hypoglycemia Hypoglycemia A1c reduction 2% A1c reduction 2%

Insulin Insulin Name OnsetPeakDuration Humalog (Lispro) 5 – 15 mins 30 – 75 mins 2 – 3 hrs Novolog (Aspart) 10 – 20 mins 1 – 3 hrs 3 – 5 hrs Regular 30 mins 2 – 5 hrs 5 – 8 hrs NPH (N) 1 – 3 hrs 6 – 12 hrs 16 – 24 hrs Lente (L) 1 – 3 hrs 6 – 12 hrs 16 – 24 hrs Lantus (Glargine) 1 hour Evenly x 24 hrs 24 – 28 hrs NPH/Regular 70/30 or 50/50 30 – 60 mins 2 – 12 hrs Up to 18 hrs RAPID INTER MED LONG MIX

Summary of Insulin Action Profiles Short (regular) Rapid (lispro, aspart, glulisine) Intermediate (NPH) Long (Glargine) Time (hours) Insulin concentration

Returns in 3 months…. Stopped drinking a gallon of sweet tea every day. No more Mcdonalds. Stopped drinking a gallon of sweet tea every day. No more Mcdonalds. Taking metformin 1000mg po bid Taking metformin 1000mg po bid BP 122/68 BP 122/68 A1c improved from 8% to 6.9% A1c improved from 8% to 6.9% What would you do differently if his blood sugar was 300 at presentation? What would you do differently if his blood sugar was 300 at presentation? Metformin not enough…start metformin and insulin, taper insulin later once well controlled Metformin not enough…start metformin and insulin, taper insulin later once well controlled

2 years later.. Doing well…blood sugars running higher. Doing well…blood sugars running higher. Meds- ASA, Statin, metformin Meds- ASA, Statin, metformin BP 144/90 BP 144/90 A1c 8.2%, cr 1.2 A1c 8.2%, cr 1.2 What are you going to do now? What are you going to do now? Htn- add ACEI Htn- add ACEI Glycemic control- add sulfonylurea Glycemic control- add sulfonylurea

2 years later…. On ASA, metformin 1000 bid, glipizide 10 bid, enalapril 20 qd, simvastatin 40 daily On ASA, metformin 1000 bid, glipizide 10 bid, enalapril 20 qd, simvastatin 40 daily BP 128/72 BP 128/72 A1c 9% A1c 9% What now? What now?

Start insulin…don’t be afraid What do you prescribe and how? What do you prescribe and how? Basal insulin Basal insulin Use NPH or lantus Use NPH or lantus Start with 10 units Start with 10 units Increase by 2-5 units every 3-5 days if Blood sugar > 150 Increase by 2-5 units every 3-5 days if Blood sugar > 150

6 months later... Doing well with glargine (lantus) 55 units daily Doing well with glargine (lantus) 55 units daily Fasting blood sugars Fasting blood sugars A1c 8.4% A1c 8.4% What is up with that? What is up with that? Check postprandials and add short acting insulin to largest meal Check postprandials and add short acting insulin to largest meal

Other things to think about with diabetic patients Reducing CV risk Reducing CV risk ASA ASA Statin Statin Blood pressure Blood pressure ACEI ACEI Reducing microvascular risk Reducing microvascular risk Eye exam Eye exam Microalbumin Microalbumin ACEI ACEI Foot exam Foot exam Immunizations Immunizations Influenza Influenza Pneumococcal Pneumococcal

Foot Exam Risk factors for diabetic foot ulcers Risk factors for diabetic foot ulcers Previous foot ulceration Previous foot ulceration Prior lower extremity amputation Prior lower extremity amputation Long duration of diabetes (>10 yrs) Long duration of diabetes (>10 yrs) Poor glycemic control (A1c >9%) Poor glycemic control (A1c >9%) Impaired vision Impaired vision

What are components of foot exam? REMOVE SHOES AND SOCKS REMOVE SHOES AND SOCKS Inspect for Inspect for Structural abnormalities Structural abnormalities Reduced joint mobility Reduced joint mobility Dryness, fissures, tinea Dryness, fissures, tinea Palpate the posterior tibialis and dosalis pedis pulses Palpate the posterior tibialis and dosalis pedis pulses Inspect footwear for proper fit Inspect footwear for proper fit Test sensation- Test sensation- Best done with ten gram monofilament Best done with ten gram monofilament

Copyright restrictions may apply. Singh, N. et al. JAMA 2005;293: Monofilament Test for Light Touch Sensation

Monofilament Test at four sites on each foot for 1-2 seconds, until the filament buckles to a “C” Test at four sites on each foot for 1-2 seconds, until the filament buckles to a “C” 90% sensitivity 90% sensitivity Increasing the testing to 10 locations on each foot increases sensitivity but more time consuming Increasing the testing to 10 locations on each foot increases sensitivity but more time consuming Tuning fork Tuning fork Lower sensitivity (55-61% sensitive) Lower sensitivity (55-61% sensitive)